Scarica l'app Stockscreener
141.85
1.03%
1.4793
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novartis Ag Adr Borsa (NVS) Ultime notizie
Novartis stock stabilizes after trial setbacks as investor pushes for board shake-up - ad-hoc-news.de
Sarepta Therapeutics Inc Share PriceSRPT, RNS News, Articles, Quotes, & Charts (NASDAQ:SRPT) - Proactive financial news
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - Zacks Investment Research
NVS Stock Quote Price and Forecast - CNN
Why Did Novartis (NYSE:NVS) Shares React to Study Results? - Kalkine Media
US markets today: Dow, S&P 500, Nasdaq futures indicate negative open, PPI data in focus; Apple, Novartis, others to watch - Upstox
HSBC upgrades Novartis stock rating to hold on pipeline clarity - Investing.com
HSBC upgrades Novartis stock rating to hold on pipeline clarity By Investing.com - Investing.com India
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Dow closes sharply lower as oil surge fuels inflation fears - Proactive financial news
Dow slides as oil nears $100, US-Canada trade tensions escalate - Proactive financial news
Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) FailureAmgen (NASDAQ:AMGN) - benzinga.com
Novartis stock falls sharply after third late-stage trial failure in a week - ad-hoc-news.de
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial - finance.yahoo.com
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - Proactive Investors
Novartis Down Over 12%, On Pace for Record Percent Decrease -- Data Talk - Moomoo
Dow Jones, S&P 500 futures indicate gap-down open while Nasdaq set for flat start; Novartis, Amgen, others to watch - Upstox
Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease - Investing.com Nigeria
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis shares fall after second major trial setback in days - The Globe and Mail
Novartis shares plunge 10% as failed drug trial clouds growth outlook - Investing.com Nigeria
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Why is Novartis stock sliding today? - Investing.com
Novartis shares fall after heart drug fails late-stage trial - in.investing.com
Novartis shares fall after heart drug fails late-stage trial By Investing.com - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal - ad-hoc-news.de
Novartis stock gains as remibrutinib data and Fabhalta growth offset cell therapy trial pause - ad-hoc-news.de
Novartis Up 5.6% After MS Pill Gains $3 Billion Sales Potential - ts2.tech
Novartis stock gains as remibrutinib MS data offsets CAR T trial pause - AD HOC NEWS
Why Is Novartis Stock Soaring Tuesday?Novartis (NYSE:NVS) - Benzinga
Novartis remibrutinib cuts MS relapse rates in Phase 3 - grafa.com
US markets today: Dow, S&P 500, Nasdaq futures indicate gap-down open; Novartis, Duolingo, energy stocks to watch - Upstox
Novartis shares rise after multiple sclerosis drug hits late-stage trial goals - Investing.com Australia
Novartis stock steadies after pause of autoimmune cell therapy trials - AD HOC NEWS
Novartis stock trades mixed as investors weigh post-earnings outlook - ad-hoc-news.de
Novartis stock trades below consensus target as post-earnings digestion continues - ad-hoc-news.de
Novartis stock holds steady as investors digest latest 2026 earnings and guidance - ad-hoc-news.de
Novartis AGADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Novartis stock holds steady as oncology and Alzheimer’s pipeline draws attention - ad-hoc-news.de
Novartis stock edges lower as investors look past recent FDA win - ad-hoc-news.de
India Central Nervous System Therapeutic Market Outlook, 2033 - grandviewresearch.com
Novartis stock holds firm after Q2 2026 growth and dual listing support - ad-hoc-news.de
Alibaba Group ADR shares decline over 4% during pre-market hours; focus on AI plans after $10 billion new issue - Upstox
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors - ChartMill
Novartis stock extends its rally as investors weigh valuation and cardiovascular data plans - Ad-hoc-news.de
Novartis stock holds above $150 after orphan drug update - Ad-hoc-news.de
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Novartis stock holds above $150 as orphan drug milestone and earnings strength support valuation - Ad-hoc-news.de
1.60%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):